Table 2: Summary of preclinical studies and ongoing clinical trials with glycolysis inhibitors.

DrugTargetGroup or cell linesPhase Reference

2-DGHKLung, breast, head and neck, pancreatic, and gastric cancersCompleted in 2009[134]
2-DGHKPatients with advanced cancer and hormone refractory prostate cancerCompleted in 2011[135]
3-BrPAHKChildhood acute lymphoblastic leukemia cell linesPreclinical [110, 121]
FX11LDH-ATumor growthPreclinical[92]

2-Deoxyglucose (2-DG), 3-bromopyruvate (3-BrPA), (FX11 [3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxilic acid]) (FX11), and dichloroacetate (DCA). Information was retrieved from http://www.ncbi.nlm.nih.gov/pubmed.